These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 29872460)

  • 1. A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes.
    DeVries JH; Meneghini L; Barnett AH; Reid T; Dain MP; Landgraf W; Vlajnic A; Traylor L; Bergenstal RM
    Eur Endocrinol; 2014 Feb; 10(1):23-30. PubMed ID: 29872460
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
    Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
    Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Baseline Characteristics on Hypoglycaemia Risk with Insulin Glargine 100 U/mL: Post Hoc Analysis of the BEYOND 7 Study.
    Wan H; Wen B; Wang X; Wang J; Zhang Y; Ning T; Duan B; Li Y; Feng W; Zhang X; Cui N; Ji L
    Diabetes Ther; 2021 Sep; 12(9):2359-2369. PubMed ID: 34286454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.
    Frier BM; Landgraf W; Zhang M; Bolli GB; Owens DR
    Diabetes Obes Metab; 2018 Dec; 20(12):2894-2898. PubMed ID: 29943493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
    Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
    Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes.
    Choudhary P; Lonnen K; Emery CJ; MacDonald IA; MacLeod KM; Amiel SA; Heller SR
    Diabet Med; 2009 Jul; 26(7):665-72. PubMed ID: 19573114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.
    Lund A; Knop FK
    Curr Med Res Opin; 2012 May; 28(5):731-6. PubMed ID: 22462528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Weekly Semaglutide Reduces HbA
    Capehorn M; Ghani Y; Hindsberger C; Johansen P; Jódar E
    Diabetes Ther; 2020 May; 11(5):1061-1075. PubMed ID: 32193837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.
    Downes MJ; Bettington EK; Gunton JE; Turkstra E
    PeerJ; 2015; 3():e1461. PubMed ID: 26664803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of glucose-lowering diabetes therapy in TECOS.
    Bethel MA; Engel SS; Stevens SR; Lokhnygina Y; Ding J; Josse RG; Alvarsson M; Hramiak I; Green JB; Peterson ED; Holman RR;
    Endocrinol Diabetes Metab; 2019 Jan; 2(1):e00053. PubMed ID: 30815579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years.
    Mertes B; Gödde S; Piorkowski M; Kramer G; Müller UA; Kuniss N
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32316649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care.
    Malawana M; Kerry S; Mathur R; Robson J
    JRSM Open; 2018 Jul; 9(7):2054270418773669. PubMed ID: 30013791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported Hypoglycaemia in Patients treated with Insulin: A Large Slovenian Retrospectively-prospective Study.
    Pongrac Barlovič D; Zavratnik A; Skvarča A; Janša K; Vukelič B; Tomažič M; Ravnik Oblak M
    Zdr Varst; 2017 Oct; 56(4):244-250. PubMed ID: 29062399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PATIENTS TREATED WITH INSULIN AND SULPHONYLUREA ARE AT INCREASED MORTALITY RISK AS COMPARED WITH THOSE TREATED WITH INSULIN PLUS METFORMIN.
    Ioacara S; Guja C; Georgescu O; Martin S; Sirbu A; Purcaru M; Fica S
    Acta Endocrinol (Buchar); 2017; 13(3):329-333. PubMed ID: 31149195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.